科兴制药：2025年度净利润1.59亿元

Core Viewpoint - The company reported a significant increase in revenue and net profit for the fiscal year 2025, driven by strong overseas market expansion and non-recurring gains from investments [1] Financial Performance - The company achieved an operating revenue of 1.541 billion yuan, representing a year-on-year growth of 9.54% [1] - The net profit attributable to the parent company was 159 million yuan, with a substantial increase in net profit excluding non-recurring gains amounting to 59.7062 million yuan compared to the previous year [1] Market Expansion - The company actively expanded its overseas market, resulting in robust growth in overseas revenue, which contributed to the overall increase in operating revenue [1] Non-Recurring Gains - The increase in non-recurring gains was primarily due to changes in the fair value of private equity funds held by the company and profits from the disposal of subsidiaries [1]